Equity Profile

MEDP

Medpace Holdings, Inc.

Health CareLife Sciences Tools & Services$16.2B

Jul20Mon

Pre-Earnings Brief

UpcomingQ2-2026After Close5:00 PM EDT

Company Snapshot

Medpace Holdings, Inc. is a leading global clinical research organization that provides comprehensive services to the pharmaceutical and biotechnology industries....

Key Metrics to Watch

EPS

Earnings per share is a key indicator of profitability and will show how well the company is managing costs and generating income.

$4.00

Revenue

Total revenue reflects the company's ability to attract clients and execute contracts, which is vital for growth in the competitive life sciences sector.

$690M

Wall Street expectations, options signals, track record, and call prep available with Pro.

MEDP Q2-2026 Earnings Preview

Context

Company Snapshot

Medpace Holdings, Inc. is a leading global clinical research organization that provides comprehensive services to the pharmaceutical and biotechnology industries. Operating in the health care sector, Medpace plays a crucial role in advancing medical research and drug development, which is increasingly important as the demand for innovative therapies continues to grow.

Earnings Scorecard·Last 8Q

EPS Beat Streak

EPS Beat Rate

100%

Avg EPS Surprise

+12.59%

Avg Stock Reaction

-0.46%

Last Quarter Recap

In Q1-2026, Medpace reported an EPS of $4.28, exceeding analyst expectations by 14.53%. However, the stock declined by 1.25% the following day, indicating market caution despite the strong earnings.

Management Promises & Guidance

Expectations

Wall Street Expectations

Analysts expect Medpace to continue its trend of strong earnings, with a consensus EPS of $4.00 for Q2-2026. The market is watching closely to see if the company can maintain its growth trajectory amid increasing competition.

Bull Case

If Medpace exceeds the EPS estimate and shows strong revenue growth, it could signal robust demand for its services, potentially leading to a positive re-rating of the stock.

Bear Case

Conversely, if the company fails to meet expectations or provides weak guidance, it could lead to a significant sell-off, especially given the high implied volatility in the options market.

Key Metrics to Watch

EPS

$4.00

Earnings per share is a key indicator of profitability and will show how well the company is managing costs and generating income.

Revenue

$690M

Total revenue reflects the company's ability to attract clients and execute contracts, which is vital for growth in the competitive life sciences sector.

Expectations

Two Questions That Matter

The print will turn on these two things.

Will Medpace's EPS exceed $4.00, and by how much?

A strong EPS could reinforce investor confidence and validate the company's growth strategy, while a miss could raise concerns.

What is the outlook for revenue growth in the coming quarters?

Revenue growth is critical for sustaining the company's market position and justifying its valuation, especially in a competitive landscape.

Edge

What the Street Is Missing

Why consensus could be wrong

The Street may be underestimating the potential for Medpace to capture additional market share in clinical research, driven by increasing demand for innovative therapies.

Supporting Evidence

Recent earnings surprises indicate stronger operational performance than analysts anticipate.

The options market pricing suggests a significant move, indicating that traders expect more volatility than the consensus reflects.

Key Risk

If Medpace's revenue growth exceeds $700M, it could challenge the current bearish sentiment.

Edge

Thesis-Break Levels

Pre-commit to what would confirm each case.

The market is debating whether Medpace can sustain its growth in a challenging environment, making these metrics pivotal.

Bull Confirmed If

An EPS of $4.20 or higher, coupled with revenue exceeding $700M, would confirm strong operational performance.

Bear Confirmed If

An EPS below $3.80 or revenue falling short of $670M would signal potential issues in client demand or operational execution.

Pre-Earnings Positioning

Options Market

Implied Move

±20.52%

Historical Avg

±1.5%

Pricing rich

The options market is pricing in a significant move, suggesting that traders expect volatility around the earnings announcement.

Options are pricing ±20.5% while MEDP has averaged ±1.5% over the last 8 prints — setup is pricing rich.

Detail

ATM IV

0.5%

30d HV

80.4%

Calls (2K)P/C Ratio: 0.20Puts (4K)

Preparation

Post-Print Playbook

Likely market behavior by outcome — not investment advice.

Beat & Raise

If Medpace beats expectations, history suggests the stock could see an average one-day move of +1.49%, confirming strong demand and operational efficiency.

In-Line / Cautious

If results are in line with expectations, the stock may react cautiously, reflecting uncertainty about future growth prospects.

Miss

A miss could lead to a decline, with historical patterns indicating an average one-day move of -0.46%, as investors reassess the company's growth trajectory.

Earnings Track Record

Preparation

What to Listen For

Call Prep

1Any updates on new client contracts or partnerships that could drive future revenue.
2Details on operational efficiencies that may impact margins.
3Insights into market trends affecting the life sciences sector.
4Management's commentary on competitive pressures and how they plan to address them.
5Guidance on expected revenue growth for the next quarter.

See the full picture

AI-powered briefs, options data, and 20 quarters of history — everything you need before earnings.

No charge today · Auto-bills $8/mo after 7 days · Cancel anytime

More Earnings This Week

5 Reports

ICICI Bank Limited

Company Snapshot

Medpace Holdings, Inc. is a leading global clinical research organization that provides comprehensive services to the pharmaceutical and biotechnology industries....

Key Metrics to Watch

EPS

Earnings per share is a key indicator of profitability and will show how well the company is managing costs and generating income.

$4.00

Revenue

Total revenue reflects the company's ability to attract clients and execute contracts, which is vital for growth in the competitive life sciences sector.

$690M

Wall Street expectations, options signals, track record, and call prep available with Pro.

MEDP Q2-2026 Earnings Preview

Context

Company Snapshot

Earnings Scorecard·Last 8Q

EPS Beat Streak

EPS Beat Rate

100%

Avg EPS Surprise

+12.59%

Avg Stock Reaction

-0.46%

Last Quarter Recap

In Q1-2026, Medpace reported an EPS of $4.28, exceeding analyst expectations by 14.53%. However, the stock declined by 1.25% the following day, indicating market caution despite the strong earnings.

Management Promises & Guidance

Expectations

Wall Street Expectations

Bull Case

If Medpace exceeds the EPS estimate and shows strong revenue growth, it could signal robust demand for its services, potentially leading to a positive re-rating of the stock.

Bear Case

Conversely, if the company fails to meet expectations or provides weak guidance, it could lead to a significant sell-off, especially given the high implied volatility in the options market.

Key Metrics to Watch

EPS

$4.00

Earnings per share is a key indicator of profitability and will show how well the company is managing costs and generating income.

Revenue

$690M

Total revenue reflects the company's ability to attract clients and execute contracts, which is vital for growth in the competitive life sciences sector.

Expectations

Two Questions That Matter

The print will turn on these two things.

Will Medpace's EPS exceed $4.00, and by how much?

A strong EPS could reinforce investor confidence and validate the company's growth strategy, while a miss could raise concerns.

What is the outlook for revenue growth in the coming quarters?

Revenue growth is critical for sustaining the company's market position and justifying its valuation, especially in a competitive landscape.

Edge

What the Street Is Missing

Why consensus could be wrong

The Street may be underestimating the potential for Medpace to capture additional market share in clinical research, driven by increasing demand for innovative therapies.

Supporting Evidence

Recent earnings surprises indicate stronger operational performance than analysts anticipate.

The options market pricing suggests a significant move, indicating that traders expect more volatility than the consensus reflects.

Key Risk

If Medpace's revenue growth exceeds $700M, it could challenge the current bearish sentiment.

Edge

Thesis-Break Levels

Pre-commit to what would confirm each case.

The market is debating whether Medpace can sustain its growth in a challenging environment, making these metrics pivotal.

Bull Confirmed If

An EPS of $4.20 or higher, coupled with revenue exceeding $700M, would confirm strong operational performance.

Bear Confirmed If

An EPS below $3.80 or revenue falling short of $670M would signal potential issues in client demand or operational execution.

Pre-Earnings Positioning

Options Market

Implied Move

±20.52%

Historical Avg

±1.5%

Pricing rich

The options market is pricing in a significant move, suggesting that traders expect volatility around the earnings announcement.

Options are pricing ±20.5% while MEDP has averaged ±1.5% over the last 8 prints — setup is pricing rich.

Detail

ATM IV

0.5%

30d HV

80.4%

Calls (2K)P/C Ratio: 0.20Puts (4K)

Preparation

Post-Print Playbook

Likely market behavior by outcome — not investment advice.

Beat & Raise

If Medpace beats expectations, history suggests the stock could see an average one-day move of +1.49%, confirming strong demand and operational efficiency.

In-Line / Cautious

If results are in line with expectations, the stock may react cautiously, reflecting uncertainty about future growth prospects.

Miss

A miss could lead to a decline, with historical patterns indicating an average one-day move of -0.46%, as investors reassess the company's growth trajectory.

Earnings Track Record

Preparation

What to Listen For

Call Prep

1Any updates on new client contracts or partnerships that could drive future revenue.
2Details on operational efficiencies that may impact margins.
3Insights into market trends affecting the life sciences sector.
4Management's commentary on competitive pressures and how they plan to address them.
5Guidance on expected revenue growth for the next quarter.